Cargando…

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?

Epigenetics refers to the regulation of gene expression mainly by changes in DNA methylation and modifications of histone proteins without altering the actual DNA sequence. While epigenetic modifications are essential for normal cell differentiation, several driver mutations in leukemic pathogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bewersdorf, Jan Philipp, Shallis, Rory, Stahl, Maximilian, Zeidan, Amer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348528/ https://www.ncbi.nlm.nih.gov/pubmed/30719265 http://dx.doi.org/10.1177/2040620718816698

Ejemplares similares

Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
por: Shallis, Rory M., et al.
Publicado: (2022)

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
por: Shallis, Rory M., et al.
Publicado: (2021)

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

P489: PROGNOSTIC IMPACT OF “MULTI-HIT” VERSUS “SINGLE-HIT” TP53 MUTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE CONSORTIUM ON MYELOID MALIGNANCIES AND NEOPLASTIC DISEASES (COMMAND)
por: Badar, Talha, et al.
Publicado: (2023)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
por: Awada, Hussein, et al.
Publicado: (2023)

Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
por: Stahl, Maximilian, et al.
Publicado: (2016)

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
por: Lewis, Russell, et al.
Publicado: (2021)

Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
por: Stahl, Maximilian, et al.
Publicado: (2020)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Investigational venetoclax combination therapy in acute myeloid leukemia – a systematic review and meta-analysis
por: Shimony, Shai, et al.
Publicado: (2022)

P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS
por: Bewersdorf, Jan, et al.
Publicado: (2023)

Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes
por: Shallis, Rory M., et al.
Publicado: (2018)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
por: Shallis, Rory M., et al.
Publicado: (2023)

BiTEs, DARTS, BiKEs and TriKEs—Are Antibody Based Therapies Changing the Future Treatment of AML?
por: Allen, Cecily, et al.
Publicado: (2021)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
por: Gbolahan, Olumide Babajide, et al.
Publicado: (2017)

Acute Myeloid Leukemia Leading to Central Diabetes Insipidus
por: Wojeck, Brian, et al.
Publicado: (2021)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
por: Uy, Natalie, et al.
Publicado: (2018)

Interferon alpha therapy in essential thrombocythemia and polycythemia vera - a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

The Epigenetic Landscape of Acute Myeloid Leukemia
por: Conway O'Brien, Emma, et al.
Publicado: (2014)

Acute Myeloid Leukemia: Aging and Epigenetics
por: Zjablovskaja, Polina, et al.
Publicado: (2019)

Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multi-center, international study
por: Stahl, Maximilian, et al.
Publicado: (2020)

Novel therapeutic options in Acute Myeloid Leukemia
por: Medinger, Michael, et al.
Publicado: (2016)

Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
por: Gambacorta, Valentina, et al.
Publicado: (2019)

Epigenetic modifications and targeted therapy in pediatric acute myeloid leukemia
por: Xu, Huan, et al.
Publicado: (2022)

A personalized approach to acute myeloid leukemia therapy: current options
por: Illangeswaran, Raveen Stephen Stallon, et al.
Publicado: (2019)

Epigenetic treatment and beyond in acute myeloid leukemia
por: Wei, Andrew
Publicado: (2018)

Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies
por: Lee, Eunyoung, et al.
Publicado: (2021)

Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia
por: Zee, Barry M., et al.
Publicado: (2021)

Epigenetics in Cancer: A Hematological Perspective
por: Stahl, Maximilian, et al.
Publicado: (2016)

Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia
por: Pandya, Bhavik J, et al.
Publicado: (2021)

Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias
por: Leone, Giuseppe, et al.
Publicado: (2008)

Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia
por: Wingelhofer, Bettina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1uml3fuhouc8jgm344pnf3kcpk